Skip to main content
Home

Main navigation

  • Home
  • News
  • About HIV
  • About us
Search
Donate
Donate now

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you.

I am a UK taxpayer and I understand that if I pay less Income and /or Capital Gains Tax than the amount of Gift Aid claimed on all my donations in the relevant tax year, it is my responsibility to pay any difference.

In our 35th year we’re asking people to donate £35 – that’s just £1 for every year we’ve been providing life-changing information. Any donation you make helps us continue our work towards a world where HIV is no longer a threat to health or happiness.

  • £5 allows us to reach millions of people globally with accurate and reliable resources about HIV prevention and treatment.
  • £10 helps us produce news and bulletins on the latest developments in HIV for healthcare staff around the world.
  • £35 means we can empower more people living with HIV to challenge stigma with our information workshops, videos and broadcasts.
Conferences

IDWeek 2019

The IDWeek 2019 conference was held in Washington DC, USA, from 2 to 6 October 2019.
Epidemiology & behaviour

Grindr users report more sexual risk, but more likely to use PrEP

24 October 2019
Side effects

Do integrase inhibitors increase the risk of diabetes?

7 October 2019
PrEP science

Switching to TAF-based PrEP improves kidney and bone markers – but does it raise cardiovascular risk?

15 October 2019
New & experimental HIV treatments

Oral cabotegravir and rilpivirine still effective at 312 weeks

14 October 2019
New & experimental HIV treatments

Ibalizumab monoclonal antibody is effective in real-world use

7 October 2019
Hepatitis C transmission & prevention

Hepatitis C vaccine fails to prevent chronic infection

7 October 2019
Sign up for our email bulletins.
Sign up

Editors’ picks from other sources

Side effects

Switching From TDF to TAF-Containing ART Carries BMI, Atherosclerotic Cardiovascular Disease Risk

The benefits of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF)-containing antiretroviral therapy (ART) are known and include preserved or improved renal function and bone mineral density in patients living with HIV (PLWH). However, the effects of the switch on body mass index (BMI) and atherosclerotic cardiovascular disease (ASCVD) risk is unclear. 
Contagion Live
7 Oct 19
Injectable & long-acting HIV treatment

Women Find Long-Acting Injectable ART 'Emotionally Freeing and Empowering'

In general, women shared many of the same positive perceptions of LA ART that men did but offered unique insight. 
Contagion Live
7 Oct 19
More editors' picks

About us

NAM is a charity based in the United Kingdom. We work to change lives by sharing information about HIV & AIDS. We believe independent, clear and accurate information is vital in the fight against HIV & AIDS.

Our information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.

Read more about us

Connect with us

  • Twitter
  • Facebook
  • YouTube
  • Instagram
Subscribe to emails & newsfeeds

Login to our clinic portal
Donate

Visit NAM’s other websites: clinic.nam.org.uk | infohep.org | prepineurope.org | about-hiv.info | pro-vich.info | hiv-lens.org

© NAM Publications 2022, all rights reserved. NAM is not responsible for the content of external websites.

Company limited by guarantee. Registered in England & Wales, number: 2707596. Registered charity, number: 1011220

Footer menu

Show — Footer menu Hide — Footer menu
  • Contact
  • Jobs
  • Terms of Use
  • Accessibility
  • Privacy Policy
  • Cookies
  • Manage cookies